Patents by Inventor Fatih Uckun
Fatih Uckun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20070015733Abstract: Methods of inhibiting virus replication of in a cell infected with a resistant strain of HIV that includes administering to the infected cell a virus replication inhibiting amount of an aryl phosphate derivative of d4T.Type: ApplicationFiled: May 30, 2006Publication date: January 18, 2007Applicant: Parker Hughes InstituteInventor: Fatih Uckun
-
Publication number: 20060293285Abstract: Specific aryl phosphate nucleoside derivatives show activity against HIV without undesirable levels of cytotoxic activity. In particular, these derivatives are potent inhibitors of HIV reverse transcriptase. Examples of aryl phosphate nucleoside derivatives include aryl phosphate derivatives of d4T having one or more substituents on the aryl group, and wherein the phosphorus of the aryl phosphate group is attached to an amino acid residue that may be esterified or substituted, such as a methoxyalaninyl group.Type: ApplicationFiled: December 9, 2005Publication date: December 28, 2006Applicant: PARKER HUGHES INSTITUTEInventor: Fatih Uckun
-
Publication number: 20060276491Abstract: The invention provides novel JAK-3 inhibitors that are useful for treating leukemia and lymphoma. The compounds are also useful to treat or prevent skin cancer, as well as sunburn and UVB-induced skin inflammation. In addition, the compounds of the present invention prevent the immunosuppressive effects of UVB radiation, and are useful to treat or prevent autoimmune diseases, inflammation, and transplant rejection. The invention also provides pharmaceutical compositions comprising compounds of the invention, as well as therapeutic methods for their use.Type: ApplicationFiled: November 17, 2003Publication date: December 7, 2006Applicant: Parker Hughes InstituteInventors: Fatih Uckun, Elise Sudbeck, Marina Cetkovic, Ravi Malaviya, Xing-Ping Liu
-
Publication number: 20060183729Abstract: Vanadium compounds for inhibiting angiogenesis useful for treating or preventing diabetic retinopathy, hemangiomas, cancers with abnormal blood vessel supply, restenosis following vascular injury, and the like.Type: ApplicationFiled: August 12, 2005Publication date: August 17, 2006Applicant: Parker Hughes InstituteInventor: Fatih Uckun
-
Publication number: 20060167090Abstract: The invention provides BTK inhibitors, methods for their identification and use, and pharmaceutical compositions comprising BTK inhibitors, including allergy treatments.Type: ApplicationFiled: June 21, 2004Publication date: July 27, 2006Applicant: Parker Hughes InstituteInventors: Fatih Uckun, Ravi Malaviya
-
Publication number: 20060106006Abstract: The invention provides methods for treating cancer and compounds that are useful for the treatment of tumors, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates useful for preparing the compounds.Type: ApplicationFiled: January 5, 2006Publication date: May 18, 2006Applicant: Parker Hughes InstituteInventors: Fatih Uckun, Yanhong Dong, Phalguni Gosh
-
Publication number: 20060046972Abstract: The present invention provides pharmaceutical compositions comprising Compound 003 or metabolites thereof in combination with one or more carboxylesterase inhibitors. The invention provides methods for inhibiting cellular proliferation associated with proliferative cell disorders in a subject by administering Compound 003 or metabolites thereof. The invention also provides methods for arresting the cell cycle. Methods of inhibiting proliferation of cells for treatment of cancer by administering Compound 003 are described.Type: ApplicationFiled: August 31, 2005Publication date: March 2, 2006Applicant: Parker Hughes InstituteInventors: Fatih Uckun, Taracad Venkatachalam
-
Publication number: 20050277620Abstract: Specific aryl phosphate nucleoside derivatives show activity against HIV without undesirable levels of cytotoxic activity. In particular, these derivatives are potent inhibitors of HIV reverse transcriptase. Examples of aryl phosphate nucleoside derivatives include aryl phosphate derivatives of d4T having one or mote substituents on the aryl group selected from the group consisting of: 3-N(CH3)2; 2,6-(CH3O)2; 4Br-2-Cl; and 2,5-Cl2, and wherein the phosphorus of the aryl phosphate group is N-linked to an methyl or ethyl ester of an amino acid residue such as a methoxyalaninyl group.Type: ApplicationFiled: May 12, 2003Publication date: December 15, 2005Applicant: Parker Hughes InstituteInventor: Fatih Uckun
-
Publication number: 20050196851Abstract: The invention provides crystal structure of the kinase domain of BTK, as well as use of the crystal structure in the design, identification, and verification of ligands that modulate BTK activity.Type: ApplicationFiled: February 13, 2004Publication date: September 8, 2005Applicant: Parker Hughes InstituteInventor: Fatih Uckun
-
Publication number: 20050198696Abstract: A transgenic zebrafish animal model for the study of haemopoietic cell differentiation, control, and screening of therapeutic agents.Type: ApplicationFiled: March 23, 2005Publication date: September 8, 2005Applicant: Parker Hughes InstituteInventors: Fatih Uckun, Alexey Benyumov
-
Publication number: 20050192266Abstract: Novel spermicidal compounds which are organometallic cyclopentadienyl metal complexes, particularly vanadium IV complexes, are described including corresponding contraceptive and therapeutic compositions and method for providing contraception and selective killing of testicular germ cells. Included among the vanadium complexes are vanadocene dichloride, vanadocene dibromide, bis (methyl cyclopentadienyl) vanadium dichloride, vanadocene diiodide, vanadocene di-pseudohalides, and others. Most active found was vanadocene diselenocyanate.Type: ApplicationFiled: September 29, 2003Publication date: September 1, 2005Applicant: Parker Hughes InstituteInventors: Osmond D'Cruz, Phalguni Ghosh, Fatih Uckun
-
Patent number: 6925388Abstract: Novel compounds that are potent inhibitors of HIV reverse transcriptase (RT) are described in the invention. Thes novel compounds also inhibit replication of a retrovirus, such as human immunodeficiency virus-1 (HIV-1). The novel compounds of the invention include analogs and derivatives of phenethylthiazolylthiourea (PETT), of dihydroalkoxybenzyloxopyrimidine (DABO), and of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). The invention additionally provides a composite HIV reverse-transcriptase (RT) nonnucleoside inhibitor (NNI) binding pocket constructed from a composite of multiple NNI-RT complexes. The composite RT-NNI binding pocket provides a unique and useful tool for designing and identifying novel, potent inhibitors of reverse transcriptase.Type: GrantFiled: December 4, 1998Date of Patent: August 2, 2005Assignee: Parker Hughes InstituteInventors: Rakesh Vig, Chen Mao, Fatih A. Uckun
-
Publication number: 20050153995Abstract: Novel compounds that are potent inhibitors of HIV reverse transcriptase (RT) are described in the invention. Thes novel compounds also inhibit replication of a retrovirus, such as human immunodeficiency virus-1 (HIV-1). The novel compounds of the invention include analogs and derivatives of phenethylthiazolylthiourea (PETT), of dihydroalkoxybenzyloxopyrimidine (DABO), and of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). The invention additionally provides a composite HIV reverse-transcriptase (RT) nonnucleoside inhibitor (NNI) binding pocket constructed from a composite of multiple NNI-RT complexes The composite RT-NNI binding pocket provides a unique and useful tool for designing and identifying novel, potent inhibitors of reverse transcriptase.Type: ApplicationFiled: October 12, 2004Publication date: July 14, 2005Applicant: Parker Hughes InstituteInventors: Rakesh Vig, Chen Mao, Fatih Uckun
-
Publication number: 20050143339Abstract: Methods for increasing the elimination half-life of key metabolites such as d4T by administering an aryl phosphate derivative of d4T having an electron withdrawing substituent on the aryl group and an amino acid substituent on the phosphate group are described. A preferred aryl phosphate derivative of d4T is HI-113 (d4T-5?-[p-bromophenyl methoxyalaninyl phosphate]). The administration of HI-113 results in more prolonged systemic exposure to the key metabolites, Ala-d4T-MP and d4T, than administration of an equimolar dose of either metabolite. Each metabolite has a significantly longer elimination half life when formed in vivo from the administration of HI-113 than when the metabolite is administered directly.Type: ApplicationFiled: October 26, 2004Publication date: June 30, 2005Applicant: Parker Hughes InstituteInventors: Fatih Uckun, Chun-Lin Chen, Taracad Venkatachalam, Zhoa-Hai Zhu
-
Publication number: 20050119322Abstract: Synthetic Phorboxazole A and derivatives thereof for the treatment of cancer, including inhibition of cancer cell growth, induction of apoptosis, and inhibition of metastises.Type: ApplicationFiled: September 28, 2004Publication date: June 2, 2005Applicants: Parker Hughes Institute, Regents of the University of MinnesotaInventors: Fatih Uckun, Rama Narla, Craig Forsyth, Chi Lee, Feryan Ahmed, Russell Cink
-
Publication number: 20050096473Abstract: This invention provides combinatorial chemistry libraries containing thiourea and urea compounds. In addition, the invention relates to methods for constructing combinatorial chemistry libraries containing thiourea and urea compounds. Furthermore, this invention relates to methods for the identification of bioactive thiourea and urea compounds as well as compositions and therapeutic methods for treating cancer.Type: ApplicationFiled: September 21, 2004Publication date: May 5, 2005Applicant: Parker Hughes InstituteInventors: Zhaohai Zhu, Chen Mao, Rama Narla, Fatih Uckun
-
Publication number: 20050075353Abstract: Quinazoline compounds and methods for the treatment of cancer and for the treatment of allergic reactions.Type: ApplicationFiled: May 24, 2004Publication date: April 7, 2005Applicant: Parker Hughes InstituteInventors: Fatih Uckun, Xing-Ping Liu, Rama Narla
-
Patent number: 6825177Abstract: Methods for increasing the elimination half-life of key metabolites such as d4T by administering an aryl phosphate derivative of d4T having an electron withdrawing substituent on the aryl group and an amino acid substituent on the phosphate group are described. A preferred aryl phosphate derivative of d4T is HI-113 (d4T-5′-[p-bromophenyl methoxyalaninyl phosphate]). The administration of HI-113 results in more prolonged systemic exposure to the key metabolites, Ala-d4T-MP and d4T, than administration of an equimolar dose of either metabolite. Each metabolite has a significantly longer elimination half life when formed in vivo from the administration of HI-113 than when the metabolite is administered directly.Type: GrantFiled: October 19, 2001Date of Patent: November 30, 2004Assignee: Parker Hughes InstituteInventors: Fatih Uckun, Chun-Lin Chen, Taracad K. Venkatachalam, Zhoa-Hai Zhu
-
Patent number: 6380190Abstract: Novel compounds that are potent inhibitors of HIV reverse transcriptase (RT) are described in the invention. The novel compounds also inhibit replication of a retrovirus, such as human immunodeficiency virus-1 (HIV-1). The novel compounds of the invention include analogs and derivatives of phenethylthiazolylthiourea (PETT), of dihydroalkoxybenzyloxopyrimidine (DABO), and of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). The invention additionally provides a composite HIV reverse-transcriptase (RT) nonnucleoside inhibitor (NNI) binding pocket constructed from a composite of multiple NNI-RT complexes The composite RT-NNI binding pocket provides a unique and useful tool for designing and identifying novel, potent inhibitors of reverse transcriptase.Type: GrantFiled: July 13, 2001Date of Patent: April 30, 2002Assignee: Parker Hughes InstituteInventors: Rakesh Vig, Chen Mao, Fatih A. Uckun
-
Publication number: 20020049189Abstract: Vanadium (IV) complexes containing a substituted or unsubstituted catecholate ligand, and the spermicidal activity of such compounds. Preferred compounds are vanadocene (IV) complexes containing alkyl substituted catecholate ligands.Type: ApplicationFiled: September 19, 2001Publication date: April 25, 2002Applicant: Parker Hughes InstituteInventors: Phalguni Ghosh, Fatih Uckun, Osmond D'Cruz